ImmuPharma (LON:IMM) Stock Price Down 6.1% - What's Next?

Key Points

• ImmuPharma's stock price fell by 6.1% to GBX 10.43 ($0.14), significantly below its previous close of GBX 11.10 ($0.15).
• The company reported a negative P/E ratio of -1,143.82 and a disappointing EPS of GBX (0.38) in its latest quarterly earnings.
• ImmuPharma focuses on peptide-based therapeutics, particularly for autoimmune diseases, with its lead program targeting Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price traded down 6.1% during trading on Thursday . The company traded as low as GBX 10 ($0.13) and last traded at GBX 10.43 ($0.14). 3,312,566 shares were traded during mid-day trading, a decline of 61% from the average session volume of 8,523,676 shares. The stock had previously closed at GBX 11.10 ($0.15).

ImmuPharma Price Performance

The company's 50 day simple moving average is GBX 4.84 and its two-hundred day simple moving average is GBX 3.44. The stock has a market capitalization of £50.87 million, a P/E ratio of -1,143.82 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.